Advanced Solid Malignancies Clinical Trial
Official title:
A Phase I, Open-label, Dose Escalation Study to Assess the Safety and Tolerability of Fluzoparib Following Single and Multiple Oral Doses in Patients With Advanced Solid Malignancies
Fluzoparib is an oral potent, selective PARP-1 and PARP-2 inhibitor. The objective of this study will be to investigate the safety and tolerability of Fluzoparib Capsule when given orally to Chinese patients with advanced solid malignancies. In addition, the pharmacokinetic profile, MTD (if possible) and efficacy of Fluzoparib will be investigated.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02080078 -
A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline
|
Phase 1 | |
| Completed |
NCT00981721 -
A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies
|
Phase 1 | |
| Terminated |
NCT00351325 -
A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies
|
Phase 1 | |
| Completed |
NCT00295243 -
Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies
|
Phase 1 | |
| Recruiting |
NCT02347228 -
Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies
|
Phase 1 | |
| Terminated |
NCT00979134 -
Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours
|
Phase 1 | |
| Completed |
NCT00997945 -
10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies
|
Phase 1 | |
| Completed |
NCT05573724 -
Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies
|
Phase 1 | |
| Completed |
NCT03736473 -
A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients
|
Phase 1 | |
| Completed |
NCT02260661 -
Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours
|
Phase 1 | |
| Terminated |
NCT01219543 -
A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.
|
Phase 1 | |
| Completed |
NCT01213160 -
Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient
|
Phase 1 | |
| Completed |
NCT00572364 -
Open Label, Dose Escalation Phase I Study of AZD2281
|
Phase 1 | |
| Completed |
NCT03363893 -
Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04606381 -
A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies
|
Phase 1 | |
| Recruiting |
NCT05315167 -
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT00879905 -
A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT00473616 -
Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan
|
Phase 1 | |
| Recruiting |
NCT05159700 -
A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01813474 -
Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies
|
Phase 1 |